Kynam Capital Management, LP: holdings and changes

Number 60 of the top 100 funds by copy return. Kynam Capital Management, LP reported 34 US stocks worth $1.8B for the quarter ending 2026-09-30 and changed 4 new, 7 added, 5 trimmed and 2 sold since 2026-06-30.

Copy return, 4 quarters+44.2%
US 500, same time+14.5%
Size$1.8B
Stocks34

Holdings

StockChangeWeightValueShares
LEGN
Legend Biotech Corp
ADD +205%10.08%$182M9,154,389
CLDX
Celldex Therapeutics INC
TRIM -5%9.09%$164M5,066,051
SNDX
Syndax Pharmaceuticals INC
8.48%$153M8,150,959
PCVX
Vaxcyte INC
TRIM -11%8.22%$148M2,607,964
VRDN
Viridian Therapeutics INC
TRIM -5%7.01%$127M6,148,000
COGT
Cogent Biosciences INC
ADD +3%6.72%$121M3,792,289
TVTX
Travere Therapeutics INC
6.52%$118M2,000,000
URGN
Urogen Pharma LTD
5.48%$99M2,434,207
VERA
Vera Therapeutics INC
ADD +4%5.36%$97M3,000,000
BEAM
Beam Therapeutics INC
ADD +38%5.33%$96M3,933,894
CTMX
Cytomx Therapeutics INC
3.18%$58M21,140,726
MBX
Mbx Biosciences INC
3.03%$55M934,799
SMMT
Summit Therapeutics
ADD +150%2.81%$51M3,000,000
RLAY
Relay Therapeutics INC
TRIM -17%2.75%$50M2,751,500
CULLINAN ONCOL
Cullinan Oncology INC
2.65%$48M3,114,132
IMCR
Immunocore Holdings Limited
2.31%$42M1,375,000
NRIX
Nurix Therapeutics INC
1.57%$28M1,194,757
PHVS
Pharvaris N V
ADD +25%1.45%$26M824,843
BNR
Burning Rock Biotech LTD-Adr
1.21%$22M1,238,563
BCRX
Biocryst Pharmaceuticals INC
1.16%$21M2,522,660
SRZN
Surrozen INC
BUY0.87%$16M486,252
STRO
Sutro Biopharma INC
0.78%$14M872,558
XENE
Xenon Pharmaceuticals INC
BUY0.58%$10M280,000
EVMN
Evommune INC
BUY0.55%$10M1,200,000
PRLD
Prelude Therapeutics INC
TRIM -4%0.50%$9M2,311,955
GERN
Geron Corp
0.47%$8M6,836,318
PBLS
Parabilis Medicines, INC.
0.45%$8M250,000
ALEC
Alector INC Com
ADD +13%0.44%$8M4,308,494
AMRN
Amarin Corp PLC Adr
0.38%$7M532,982
IMPRIMIS PHARM
Imprimis Pharmaceuticals, INC.
BUY0.21%$4M124,655
CRBU
Caribou Biosciences INC
0.18%$3M2,503,302
PROQR THRAPEUT
Proqr Thrapeutics N V
0.14%$3M1,566,317
ENGN
Engene Therapeut
0.05%$900k457,855
TRAW
Traws Pharma INC
0.00%$100k84,400
INSM
Insmed INC.
SELL0%was $11M0
CADL
Candel Therapeutics INC
SELL0%was $1M0

Copy return each quarter

HeldFund copyUS 500
2023-09-30 → 2023-12-31+27.3%+11.2%
2023-12-31 → 2024-03-31+29.0%+10.0%
2024-03-31 → 2024-06-30-2.1%+4.0%
2024-06-30 → 2024-09-30+13.2%+5.4%
2024-09-30 → 2024-12-31-5.0%+2.1%
2024-12-31 → 2025-03-31-17.7%-4.6%
2025-03-31 → 2025-06-30+0.2%+10.5%
2025-06-30 → 2025-09-30+29.5%+7.8%
2025-09-30 → 2025-12-31+41.8%+2.4%
2025-12-31 → 2026-03-31+6.4%-4.6%
2026-03-31 → 2026-06-30+8.4%+14.8%
2026-06-30 → 2026-09-30-11.9%+2.1%

The copy return buys the fund's reported stocks on the day after the filing became public and holds them for one quarter, so it measures what anyone reading the filings could have done.

All top 100 funds, live

Other top funds

Nextech Invest LTD.Venrock Adviser, LLCFairmount Funds Management LLCTalos Eurisko Asset Management LPAnalog Century Management LPQvt Financial LPBroad Peak Investment Advisers Pte LTDWs Management LllpBvf INC/IlParadigm Biocapital Advisors LPOak Grove Capital LLCCm Wealth Advisors LLCAvidity Partners Management LPFirst Light Asset Management, LLCLogos Global Management LPSummit Street Capital Management, LLCMadison Avenue Partners, LPDivisar Capital Management LLCTcg Crossover Management, LLCOptimus Prime Fund Management Co., LTD.Value Aligned Research Advisors, LLCBraidwell LPRedmile Group, LLCOrbimed Advisors LLCMpm Bioimpact LLCCloudalpha Capital Management Limited/Hong KongGeneral Pension Society Pzu Joint Stock CoAmanah Holdings TrustSlate Path Capital LPDeep Track Capital, LP